-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
WHO sets out concerns over US vaccine trial in G.Bissau
The World Health Organization on Friday voiced serious concerns over a planned US-funded hepatitis B vaccine trial on newborn babies in junta-run Guinea-Bissau, questioning it on scientific and ethical grounds.
The WHO insisted in a statement that the existing hepatitis B birth dose vaccine was an "effective and essential" public health intervention, with a proven record.
The agency's latest statement comes two months after an advisory panel -- appointed by US health chief Robert F. Kennedy Jr -- voted to stop recommending that all newborns in the United States receive a hepatitis B vaccine.
Kennedy has long been a vocal sceptic of vaccines, and his department says the Guinea-Bissau study seeks to "answer questions about the broader health effects" of the vaccine and "fill existing evidence gaps".
The US move to end the decades-old recommendation is the panel's latest contentious about-face concerning vaccines.
Defending the existing vaccine, the WHO said Friday: "It prevents life-threatening liver disease by stopping mother-to-child transmission at birth.
"It has been used for over three decades, with more than 115 countries including it in their national schedules," it added.
Protecting newborns with the vaccine was also important for national and global elimination efforts, said the agency.
Already on Wednesday WHO chief Tedros Adhanom Ghebreyesus had branded the planned trial in the West African nation "unethical".
- 'Significant concerns' -
In its statement Friday, the organisation elaborated on its concerns, based on what it knew of the US trial.
"WHO has significant concerns regarding the study's scientific justification, ethical safeguards, and overall alignment with established principles for research involving human participants," it said.
The vaccine has a "proven safety record across decades of use", and is effective in preventing 70 to 95 percent of cases of mother-to-child transmission" it added.
A study giving a proven life-saving intervention to some but not others exposes newborns to "potentially irreversible harm", it said.
It also argued that placebo or no-treatment vaccine trials "are only acceptable when no proven intervention exists" -- or when such as design was "indispensable" for other reasons.
"Neither condition appears to be met," it said.
There was insufficient scientific justification for the study, said the WHO, and the trial's design "raises a significant likelihood of substantial risk of bias".
Since President Donald Trump appointed Kennedy, the US government has initiated a major overhaul of vaccine policy, prompting growing concerns among the medical community.
In January 2025, the United States handed its one-year withdrawal notice to the WHO, Kennedy saying last month that the Geneva-based organisation had "trashed everything that America has done for it".
A.Taylor--AT